Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 1.00 |
| ▸ | EGFR | P00533 | 13/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 10/20 | 1.00 |
| ▸ | FLT1 | P17948 | 10/20 | 1.00 |
| ▸ | FLT4 | P35916 | 10/20 | 1.00 |
| ▸ | AXL | P30530 | 1/20 | 0.61 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.61 |
| ▸ | MERTK | Q12866 | 1/20 | 0.61 |
| ▸ | EPHA2 | P29317 | 5/20 | 0.58 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | KIF5B | P33176 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2138023 | 0.91 | KDR (1.00) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL2140901 | 0.88 | FLT1 (0.98) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL2140918 | 0.88 | EGFR (1.00) | KDREGFRFGFR1FLT1FLT4 | |
| Hydrochloric Acid SCHEMBL27218181 | 0.88 | FLT1 (1.00) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL17179599 | 0.86 | KDR (0.81) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL2204539 | 0.84 | KDR (0.73) | KDREGFRFGFR1FLT1FLT4 | |
| Hydrochloric Acid SCHEMBL7209985 | 0.83 | KDR (0.70) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL3186078 | 0.82 | KDR (0.71) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL3123730 | 0.82 | EGFR (0.80) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL2136908 | 0.82 | EGFR (1.00) | KDREGFRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190002433-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2019-01-03 | — | — | US | claimed |
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2018-04-12 | — | — | US | claimed |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | ASTRAZENECA AB (SE) | 2016-05-12 | — | — | US | claimed |
| US-20110065736-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | claimed |
| US-20070265286-A1 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB | 2007-11-15 | — | — | US | claimed |
| US-7173038-B1 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | claimed |
| EP-1244647-B1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-21 | — | — | EP | claimed |
| JP-3522727-B2 | — | — | 2004-04-26 | — | — | JP | claimed |
| JP-2003513089-A | — | — | 2003-04-08 | — | — | JP | claimed |
| EP-1244647-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | claimed |
| WO-2001032651-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2001-05-10 | — | — | WO | claimed |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FOUNTAIN THERAPEUTICS INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-20210276972-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2021-09-09 | — | — | US | disclosed |
| US-20200262811-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2020-08-20 | — | — | US | disclosed |
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | GENZYME CORPORATION (US) | 2019-10-29 | — | — | US | disclosed |
| US-20030144298-A1 | Using a combination of an angiogenisis inhibitor and a hypotensive agent for use in treating diseases associated with angiogenesis; an endothelial growth factor receptor tyrosine kinase inhibitor; antidiabetic, -arthritis agents | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
| EP-1272186-A1 | THERAPEUTIC COMBINATIONS OF ANTIHYPERTENSIVE AND ANTIANGIOGENIC AGENTS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| EP-1244647-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001074360-A1 | THERAPEUTIC COMBINATIONS OF ANTIHYPERTENSIVE AND ANTIANGIOGENIC AGENTS | ASTRAZENECA AB (SE) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001032651-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | KDR 3/4885EGFR 199/4885FGFR1 161/4885 |
| US-20210276972-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 207/4885FGFR1 154/4885 |
| US-20110065736-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | FLT1, FLT4, KDR | KDR 3/4885EGFR 183/4885FGFR1 143/4885 |
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 179/4885FGFR1 196/4885 |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FGFR1, FRS2, FGFR2 | KDR 5/4885EGFR 475/4885FGFR1 1/4885 |
| US-20070265286-A1 | Quinazoline derivatives as VEGF inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 183/4885FGFR1 143/4885 |
| US-20030144298-A1 | Using a combination of an angiogenisis inhibitor and a hypotensive agent for use in treating diseases associated with angiogenesis; an endothelial growth factor receptor tyrosine kinase inhibitor; antidiabetic, -arthritis agents | TEK, TIE1, FLT1 | KDR 5/4885EGFR 51/4885FGFR1 9/4885 |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 181/4885FGFR1 135/4885 |
| US-20200262811-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 181/4885FGFR1 135/4885 |
| US-20190002433-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 179/4885FGFR1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.